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Paracrine regulation of differentiation has been demonstrated to be
implicated in the induction and maintenance of differentiation in
several different developmental systems. Perhaps the best docu-
mented, and now classical, model, is the induction of growth and
differentiation in prostatic epithelium where stimulation by testos-
terone requires the presence of functional receptors in the stromal
component of the gland (Cunha et al, 1983). Treatment of stromal
fibroblasts induces the release of keratinocyte growth factor (KGF,
FGF-7) which binds to a specific receptor of the FGFR family,
Bek, only present on the epithelium, and elicits proliferation and
maturation of the epithelium (Yan et al, 1992; Planz et al, 1998).
Similar indirect hormonal control of differentiation has been
demonstrated in the intestine (Kedinger et al, 1987), where the
action of hydrocortisone requires the presence of stroma in order
to induce differentiation in the enterocytes, and in the lung, where
the perinatal production of surfactant lipid by type II pneumocytes
is regulated by hydrocortisone via stimulation of lung fibroblasts
(Post et al, 1984; Nielsen et al, 1992). While direct cell contact, or
indirect cell–cell interaction via constituents of the extracellular
matrix, may be implicated in some of these interactions (Simon-
Assmann, 1986), there is also a significant role for diffusible
factors, such as KGF in the prostate (Yan et al, 1992). In the lung,
a factor has been described, called fibrocyte-pneumocyte factor
(FPF) (Post et al, 1984), detectable in conditioned medium from
primary cultures of lung fibroblasts, but so far, this has not been
purified to homogeneity, cloned, or fully characterized.
Differentiating activity is present in fibroblast-conditioned
medium (CM) from cell lines (McCormick et al, 1995), but not
restricted to lung fibroblasts.
The prospect of inhibiting tumour growth by induction of differ-
entiation has received considerable attention and has given
promising results in vitro and in vivo. However, the use of agents
such as the planar-polar compound hexamethylene bisacetimide
(HMBA) (Marks et al, 1996), has had limited clinical success due
to the difficulty in maintaining the high concentration required and
ensuing problems of toxicity. More promising results have been
obtained using retinoids, where enhanced response rates have been
obtained in acute promyelocytic leukaemia (Drach et al, 1993) and
potentiation with HMBA is possible (Taimi et al, 1998). This
suggests that other natural high potency regulators of differentia-
tion, such as growth factors or cytokines implicated in paracrine
control of differentiation, may be worthy of further exploration.
Speirs et al (1991) showed that a paracrine factor from lung fibro-
blasts treated with dexamethasone (DX, a synthetic analogue of
hydrocortisone), was able to induce differentiation (induction of
pulmonary surfactant synthesis), in the A549 cell, a tumour of type II
pneumocyte or Clara cell origin. McCormick et al (1995), in a screen
of potential candidates for this paracrine activity, showed that insulin,
interferon-a (IFN-a) and interleukin (IL)-6 are all active inducers of
differentiation, by demonstrating induction of alkaline phosphatase
(AP), another marker of type II cell differentiation. As IL-6 was one
of the most active, we have now examined other growth factors in the
same family. We have also used blocking antibodies to determine
whether any of these are present, and active, in fibroblast-CM.
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Summary The role of the interleukin-6 (IL-6) group of cytokines in differentiation of two lung adenocarcinoma cell lines has been examined
using induction of alkaline phosphatase and expression of surfactant protein A. Oncostatin M was the most active and potent for alkaline
phosphatase in A549 cells, with IL-6 having similar activity but less potency. Neither cytokine induced alkaline phosphatase in NCI-H441 cells,
although induction was obtained with lung fibroblast-conditioned medium. Surfactant protein A was induced in NCI-H441 cells by conditioned
medium and dexamethasone and, to a much lesser extent, by oncostatin M or IL-6. Induction of alkaline phosphatase and surfactant protein
A were both dexamethasone-dependent, though some induction of surfactant protein A was obtained with interferon-a in the absence of
dexamethasone. The activity present in lung fibroblast-conditioned medium suggests paracrine control, but this appears not to be due to
oncostatin M or IL-6 as disabling antibodies to either cytokine were not inhibitory, and, although alkaline phosphatase was induced in A549 by
both cytokines, it was only induced by conditioned medium in NCI-H441 cells. Furthermore, surfactant protein A was induced in H441 by
conditioned medium to a much greater extent than by oncostatin M or IL-6. These data demonstrate that cytokines of the IL-6 group have
potential as differentiation inducers in lung adenocarcinoma cells and that there is an equivalent paracrine factor(s) in lung fibroblast
conditioned medium. As the production of this factor by fibroblasts is not enhanced by glucocorticoid, although the response of the target cell
is, it would appear to be distinct from the fibrocyte pneumocyte factor previously described by Post et al 1984 Nature 308: 284–286. © 2000
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Gp130 receptor sub-unit (Taga and Kishimoto, 1997). Others 
in the group include IL-11, ciliary neurotropic factor (CNTF),
oncostatin-M (OSM) and leukaemia inhibitory factory (LIF).
Granulocyte-colony stimulating factor (G-CSF) has been included
in this group (Rose and Bruce, 1991; Bruce et al, 1992), and also
acts via the JAK-STAT pathway (Akira, 1997) but most recent
reviews exclude it (e.g. Taga and Hishimoto, 1997). G-CSF, LIF
and IL-11 are differentiation and proliferation factors, active prin-
cipally in the haematopoietic system (Taga et al, 1992; Katayama
and Ogawa, 1994), and CNTF in the neural system (Lillien et al,
1990). LIF is an inhibitor of differentiation of embryonal stem
(ES) cells (Boeuf et al, 1997; Niwa et al, 1998), and the other
members of the group have similar, though less potent, activity on
ES cell differentiation (Bruce et al, 1992).
In the present report we have confirmed the activity of IL-6 and
shown that OSM is significantly more active and potent than IL-6
in the induction of A549 differentiation and, like all other factors
previously investigated, with the exception of FGF-2, is dependent
on the presence of DX for its activity. LIF and IL-11 are also
active, though less so than OSM, and CNTF and G-CSF are
inactive. Transforming growth factor (TGF)-b is inhibitory in this
system (McCormick et al, 1995) and we now show that it blocks
the inductive activities of OSM and IL-6.
The potential roles of IL-6 and OSM as paracrine factors
produced by lung fibroblasts were tested by use of disabling anti-
bodies. The results failed to show any reduction in the inductive
effect of CM, in spite of demonstrable inhibition of induction 
of AP by recombinant human OSM (rhOSM) and rhIL-6.
Furthermore, DX and CM induced AP and SPA in NCI-H441
cells, another Type II/Clara cell-derived tumour cell line, while
OSM and IL-6 induced SPA but not AP.
MATERIALS AND METHODS
Cell culture
A549 (CCL-185) and NCI-H441 (HTB-174) cells were obtained
from the American Tissue Culture Collection (ATCC) and main-
tained in a 50:50 mixture of Dulbecco’s modification of Eagle’s
medium and Ham’s F10 (F10:DMEM) (Life Technologies),
supplemented with 10% fetal bovine serum (FBS; Globepharm).
MOG-LF113 cells, used as a source of conditioned medium, are
normal human diploid lung fibroblasts derived from a first
trimester embryo. They were used between generations 10 and 30.
Cell lines were tested monthly for mycoplasma by fluorescence
staining with Hoechst 33258 (Chen, 1977).
Conditioned medium
Fibroblast CM was prepared from LF113 cells, seeded at 2 ´ 104
cells ml–1, grown to confluence, and grown on for 8 days in
F10:DMEM with 0.5% FBS. To prepare CM, the medium was
replaced with serum-free F10:DMEM, or, to prepare DXCM, with
serum-free F10:DMEM containing 0.25 mM DX, for a further 
3 days, collected and stored frozen. CM was thawed, filtered
through a 0.22 mm Millipore GV filter, and used at 50% (unless
otherwise indicated) in fresh serum-free F10:DMEM.
Alkaline phosphatase activity
Cell monolayers in microtitration plates were washed in 0.15 M
sodium chloride (NaCl) and frozen and thawed 3 ´ in 10 ml 0.15 M
NaCl. AP was assayed by the dephosphorylation of p-nitrophenyl
phosphate at pH 8.5 (Sigma kit #104). The concentration of
coloured product, p-nitrophenol (PNP), was determined by
absorbance at 310 nm, with reference to a standard curve. Enzyme
activity is expressed as mmol PNP produced h–1 10–5 cells (counted
in replicate wells). The reaction was shown to be linear over the
range of activities measured (data not shown).
Growth factors, antibodies and other reagents
IL-6 was obtained from Boehringer Mannheim, OSM from NBS
Biologicals, LIF and IL-11 from Genetics Institute, G-CSF from
Amgen, CNTF from Pepro Tech, TGF-b from British
Biotechnology, anti-IL-6 antibody from NIBSC and anti-OSM
from R&D. DX was obtained from Sigma (#D1756) and used at
0.25 mM, unless indicated otherwise. Actinomycin D (#A1410)
and cycloheximide (#C6255) were obtained from Sigma and used
at 5.0 mg ml–1, at which concentration no loss of viability was
observed using naphthalene black as a viability stain (Freshney,
2000).
Assay for exposure to growth factors and CM
A549 cells were seeded at 5 ´ 104 cells ml–1, grown for 3 days and
the medium changed to serum-free F10:DMEM. Growth factors or
CM were added for a further 3 days and the AP activity measured
as above.
Exposure to antibodies
CM or growth factors were exposed to antibodies at a range of
concentrations, including zero, in polypropylene microtubes
(Eppendorf) for 2 h at 37°C, immediately before addition to assay
plates, and the assay continued as above.
Northern blots
Northern blots were prepared by standard procedures (Sambrook
et al, 1989). Blots were probed with Probes 1255 and 2305,
obtained from Riken.
RESULTS
Incubation of A549 cells for 3 days with DX alone, in the absence
of serum, induced AP three-fold at 0.25 mM (P < 0.0001) and 4.8-
fold at 10 mM (P < 0.0001), but not at all at 50 nM (Figure 1). IL-6
added for 3 days in the presence of 0.25 mM DX, gave a dose-
dependent increase in AP activity, reaching a maximum at 
2.5 mg ml–1, amounting to 2.3 ´ DX alone in 0.25 mM (P < 0.0001),
and 2 ´ DX alone in 10 mM (P < 0.0001).
OSM, under similar conditions, induced AP 2.6-fold at 
20 ng ml–1 (P = 0.0036), and was, therefore, both more potent and
more active than IL-6 (Figure 2). Like IL-6, it required DX for
activity; it was inhibitory on its own. LIF gave 50% induction at
200 U ml–1 (P < 0.0001) and IL-11 60% induction at 1000 U ml–1
(P = 0.0001), in the presence of 0.25 mM DX (Figure 3), and 
were inactive in the absence of DX. CNTF and G-CSF gave no
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concentrations of IL-6 and OSM showed about 15% more activity
than either IL-6 or OSM alone but was not additive (data not
shown).
TGF-b was shown previously to be inhibitory for the induction
of AP in A549 cells (McCormick et al, 1995) and was able to
obliterate the effects of either IL-6 or OSM in the present series
(Figure 4).
As previously reported (McCormick et al, 1995), CM from a
lung fibroblast cell line, LF113, induced AP activity in the presence
of DX. Unlike the induction of pulmonary surfactant (Speirs et al,
1991), prior exposure of the fibroblasts to DX did not increase the
AP-inductive capacity of CM, and, in fact, reduced its potency,
perhaps due to down regulation of IL-6 (McCormick et al, 1995)
(Figure 5). The induction by CM was completely blocked by 5.0 mg
ml–1 cycloheximide and 5.0 mg ml–1 actinomycin D (Figure 6).
In order to determine whether IL-6 or OSM were potential
candidates for paracrine differentiation factors present in CM, CM
was treated with disabling antibodies to IL-6 and OSM. While
both antibodies inhibited their respective cytokines in positive
controls (Figure 7 B, D), no inhibition of activity in CM was
observed (Figure 7 A, C).
AP activity is used in these experiments as a marker of differen-
tiation. To confirm that differentiation was being induced, expres-
sion of mRNA for SPA was determined in A549 and NCI-H441
cells. There was little induction of SPA by DX alone in A549.
CM+DX, DXCM, OSM and IL-6 all showed less SPA expression
than the serum-free control (SF) or DX alone, although the DX
values were always higher than CM or cytokines alone. In H441
cells, SPA and AP were both induced by DX and CM (Figures 8 and
9). DX (P = 0.02), CM+DX (P = 0.0003) and DXCM (P = 0.003)
induced AP, with greatest activity in CM+DX, but OSM and IL-6
showed no AP induction over DX alone. IFN-a, previously shown
to induce AP in A549 cells (McCormick et al, 1995), also induced
AP in H441 (P = 0.06). Preliminary data from Northern analysis
suggest that CM+DX and DXCM induce SPA expression in H441,
while OSM, IL-6, insulin and interferon, in the presence of DX,
also induced SPA relative to DX alone (Figure 9), although
expression was never as great as with CM+DX.
DISCUSSION
Previous results indicated that IL-6 was an active inducer of AP 
in A549 cells in the presence of DX (McCormick et al, 1995),
prompting the investigation of other members of this family of
cytokines. Among those studied, the highest activity and greatest
potency were found with OSM, with 2.6-fold stimulation at 10 ng
ml–1, compared with 2.3-fold stimulation with IL-6 at 2.5 mg ml–1.
Activity was also seen with LIF (50% at 200 U ml–1) and IL-11
(60% at 1000 U ml–1). The response to IL-11 may have been cross-
reaction with one of the other receptors, as the concentration of
ligand was quite high, but the response to LIF, although modest,
may have been through the LIF receptor, known to be expressed
on A549 (Piquet-Pellorce et al, 1994). TGF-b stimulates A549
cells to produce IL-11 and DX inhibits this stimulation (Wang et
al, 1999) so, even if IL-11 receptors are present on A549 the stim-
ulatory role of TGF-b and inhibitory role of DX would conflict
with the effects seen here with AP induction. No significant
activity was found with G-CSF and CNTF. Activities may be
ranked as follows: OSM > IL-6 > LIF > IL-11 > G-CSF > CNTF.
This group of cytokines has been shown to share activities in
other systems, e.g. inhibition of differentiation in ES cells, where
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Figure 1 Effect of DX concentration on induction of AP by IL-6 in A549
cells. Mid-log phase A549 cells were incubated in microtitration plates in
serum-free medium for 3 days in DX at three different concentrations and a
range of concentrations of IL-6 from 0.5 to 12.5 mg ml–1, and assayed for AP
as described in the Methods. Means ± s.e.m.
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Figure 2 Effect of DX on induction of AP by OSM in A549 cells. Mid-log
phase A549 cells were incubated in microtitration plates in serum-free
medium for 3 days with or without DX and a range of concentrations of OSM
from 0.1 to 100 ng ml–1, and assayed for AP as described in the Methods.
Means ± s.e.m884 C McCormick and RI Freshney
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Figure 3 Induction of AP by other members of the IL-6 family. Mid-log phase A549 cells were incubated in microtitration plates in serum-free medium for 
3 days with or without DX and a range of concentrations of LIF, IL-11, CNTF, and G-CSF, and assayed for AP as described in the Methods. Means ± s.e.mLIF has the greatest effect (Smith et al, 1988). It has been
suggested that the shared activity results from a common interac-
tion with the Gp130 subunit of the receptor, which they all share,
while specificity is determined by the a-subunit which is unique to
each cytokine (Gearing et al, 1992; Taga and Kishimoto, 1997).
Low concentrations of the active cytokines are additive, while
high concentrations are not (data not shown), again suggesting a
shared receptor.
Activity was only seen in the presence of DX at a minimum
concentration of 0.25 mM. The effect of DX is likely to be multi-
factorial. Glucocorticoids are known to influence gene transcription
when the nuclear receptor binds to the glucocorticoid response
element (GRE) (Reichardt and Schutz, 1998) and modulate genes
activated by OSM (Haselmann and Goppelt-Struebe, 1997). In addi-
tion, they can influence signal transduction by interaction with the
IL-6 signal transduction pathway, JAK tyrosine kinase and the STAT
transcriptional activator (Takeda et al, 1998), and by inhibition of
protein kinase C (PKC) action downstream of PKC activation (Tian
et al, 1999). They can also affect cytokine receptor presentation
(Wiegers and Reul, 1998), inhibit extracellular proteases (Freshney,
1985) which, in turn, can block activation of TGF-b(Cai et al, 1997).
DX has also been shown to alter the extracellular matrix
(Mackie et al, 1988) and extracellular matrix has been shown to be
important in promoting the expression of the type II phenotype in
culture (Liu and Mautone, 1996; Alcorn et al, 1997). In the current
system DX has been found to increase the synthesis of a fraction of
heparan sulphate present in the medium of DX-treated A549 cells.
This fraction is heparinase and heparitinase-sensitive and can
replace DX in the induction of AP in A549 cells by CM, IL-6 and
OSM (Yevdokimova and Freshney, 1997). CNTF, a member of the
IL-6 family, has been shown to interact with matrix in the differen-
tiation of type 2 astrocytes (Lillien et al, 1990), and heparan
Induction of lung differentiation by oncostatin 885
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Figure 4 Effect of TGF-b on induction of AP by OSM. Mid-log phase A549 cells were incubated in microtitration plates in serum-free medium for 3 days with or
without DX and OSM (A) or IL-6 (b) and a range of concentrations of TGF-b, and assayed for AP as described in the Methods. Means ± s.e.m
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Figure 5 Induction of AP in lung fibroblast-conditioned medium (CM). CM
was prepared as described in the Methods and diluted in serum-free 
F10:DMEM in the percentages shown. Mid-log phase A549 cells were
incubated in microtitration plates in serum-free medium for 3 days with
different concentrations of condition medium and assayed for AP as
described in the Methods. CM is fibroblast-conditionED medium diluted in
F10:DMEM; CM+DX is CM with 0.25 mM DX added; DXCM is CM prepared
from lung fibroblasts, LF113, in the presence of 0.25 mM DX. Means ± s.e.msulphate proteoglycan (HSPG) has been implicated in receptor
dimerization (Schlessinger et al, 1995). It would appear that, if
induction of an HSPG is the main role of DX in this system, then
either the HSPG shares affinity for a wide range of growth factors,
including IF-a, IF-b, OSM, IL-6 and insulin, all of which have
been shown to have DX-dependent activity (McCormick et al,
1995, and this report), or they all induce a secondary autocrine
factor to be produced by the target cells, A549 or H441, and the
specificity of the HSPG is directed towards that factor.
The activities of both OSM and IL-6 were inhibited by TGF-b,
consistent with the inhibitory role proposed for TGF-b in type II
cell maturation (Torday and Kourembanas, 1990; Beers et al,
1998), where TGF-b in the lung remains high during embryonic
development but falls just before parturition when hydrocortisone
levels rise, inhibit TGF-b3 gene expression and induce surfactant
production (Jaskoll et al, 1996). Although TGF-b is low at parturi-
tion, it can be induced by hydrocortisone in embryonic rat lung
fibroblasts and may be implicated in the morphogenesis of
bronchial epithelial cells (Wang et al, 1995). Preparation of fibro-
blast-conditioned medium in the presence of DX decreased its
inductive effect on A549 cells (see Figure 5) which would be
compatible with induction of TGF-b in the fibroblasts. The effect
of TGF-b on SPA expression was not investigated in this study, but
inhibition in H441 has been reported (Whitsett et al, 1992).
As IL-6 and OSM are both potential candidates for the inducing
activity of CM, blocking antibodies were used to determine
whether they could account for all or part of the activity of CM.
Antibodies to IL-6 and OSM, selected for their ability to inhibit
the pure cytokine, were unable to inhibit CM. This suggests that
the major active component of CM is neither IL-6 nor OSM,
although it is acknowledged that native IL-6 or OSM in condi-
tioned medium may be in a different form from the recombinant
cytokines to which the antibodies were raised, e.g. bound to a
cofactor such as a proteoglycan (Yevdokimova and Freshney,
1997) or by post-translational modification. However, CM, in the
presence of DX, induced both AP activity and SPA gene expres-
sion in H441 cells, while OSM and IL-6 induced SPA but not AP,
although some AP-inducing activity was seen with IFN-a. This
suggests that the activity in CM is not IL-6 or OSM. Experiments
with anti-gp130 antibody would confirm that activity is due to a
member of this family.
It is possible that activity is due to a combination of factors.
OSM, LIF, and/or another member of the IL-6 group, combined
with IFN-a or IFN-b could generate AP-inducing activity in A549
cells equivalent to that of CM, but would not account for the
induction of AP in H441 cells. A combination of optimal concen-
trations of IFN-a, IL-6 and insulin were shown previously to have
equivalent activity to conditioned medium (McCormick et al,
1995), but this would still show inhibition with anti-IL-6, subject
to the reservations above. Keratinocyte growth factor (KGF, FGF-
7) has been shown to induce alveolar type II cell maturation
(Shiratori et al, 1996; Chelly et al, 1999) but as it had no activity in
AP induction with A549 (data not shown) it was not included in
this series. It could, however, have an important role in surfactant
induction, if not in A549 cells, perhaps in H441.
Induction of SPA expression confirmed the differentiating
activity of CM+DX in H441 cells and suggested that, unlike AP,
SPA is induced by OSM, IL-6 insulin and IFN in the presence of
DX. IF was also active, though less so, in the absence of DX. This
was distinct from the response of A549 cells, where all conditions,
other than DX alone, decreased SPA expression, though less so in
the presence of DX. It would appear that the regulation of AP and
SPA may be different and that A549 clearly responds differently
from H441 and may be progressing along a different lineage.
Induction of AP suggests that this is not towards a type I pneumo-
cyte, but it may be towards a Clara cell or other secretory
phenotype. As Clara cells also make SPA (Kalina et al, 1992) the
second may be more likely. Alternatively, inappropriate type II
886 C McCormick and RI Freshney
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Figure 6 Effect of actinomycin D and cycloheximide on induction of AP. Mid-log phase A549 cells were incubated in microtitration plates in serum-free medium
for the time shown, with or without CM, in the presence or absence of 0.25 mM DX, and with or without 5 mg ml–1 actinomycin D (ActD) or cycloheximide (Cyc)
and assayed for AP as described in the Methods. Means ± s.e.mInduction of lung differentiation by oncostatin 887
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Figure 7 Effect of disabling antibodies to OSM and IL-6 on the induction of AP by A549 cells. Conditioned medium, or recombinant human cytokine, were
pretreated with antibody as described in Methods and then incubated with A549 cells as previously, and AP assayed. (A) Media pre-treated with anti-IL-6
antibody, (B) rhIL-6 pre-treated with anti-IL-6 antibody, (C) Media pre-treated with anti-OSM antibody, (D) rhOSM pretreated with anti-OSM antibody. SF, serum-
free F10:DMEM; DX, F10:DMEM with 0.25 mM dexamethasone; CM+DX, fibroblast conditioned-medium with 0.25 mM DX; DXCM, medium conditioned by
fibroblasts in the presence of 0.25 mM DX. Means ± s.e.mdifferentiation by A549 may be due to a greater sensitivity (than
H441) to the absence of the correct extracellular matrix
constituents required for type II maturation (Fraslon et al, 1993;
Griffin et al, 1993). Although different probes were used for the
two cell lines, results were similar for both probes with SF, CM,
DX, CM+DX and DXCM in A549 (cytokines not tested; data not
shown), but the possibility remains that apparent differences from
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Figure 8 Effect of fibroblast conditioned-medium (CM) and cytokines on AP
activity in NCI-H441 cells. Mid-log phase H441 cells were incubated in
microtitration plates in serum-free medium for 3 days with or without 0.25 mM
DX, 50% CM, 10 ng ml–1 OSM, 2.5 mg ml–1 IL-6, 2.5 mg ml–1 insulin and 20 ng
ml–1 IF-a, and assayed for AP as described in the Methods. Means ± s.e.m
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Figure 9 Effect of fibroblast conditioned-medium (CM) and cytokines on
expression of SPA mRNA in A549 and NCI-H441 cells. Radioactive cDNA
was prepared from Probe 155 or 2305, specific for SPA mRNA, and
hybridized to RNA extracted from A549 or NCI-H441 cells after treatment for
3 days with 50% CM, 10 ng ml–1 OSM, 2.5 mg ml–1 IL-6, 2.5 mg ml–1 insulin, or
20 ng ml–1 IF-a, in the presence and absence of 0.25 mM DX
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Figure 10 Densitometric scans from autoradiographs in Figure 9. The ODs
in each lane were normaliZed to the GAPDH values. OD units are nominal.
Relative values can be compared within one, but not between two
experimentsH441 were due to different hybridization characteristics of the two
probes or differences in the regulation of expression of mRNA for
SP-A1 and SP-A2 in the two cell lines (Scavo et al, 1998).
In conclusion, IL-6 and OSM are among the most active
cytokines in the induction of AP activity in A549 cells, but the lack
of inhibition of OSM and IL-6 by blocking antibodies, and their
lack of AP-inducing activity with H441 cells, suggests that the
active paracrine factor(s) produced by lung fibroblasts have not yet
been identified. Purification or cloning of the factor or factors
present in conditioned medium, plus the recreation of the correct
microenvironment with extracellular matrix constituents such as
laminin and proteoglycans, and the presence of cells or condi-
tioned medium from primary cultures from the type II lineage,
may throw further light on this.
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